Health
Patrys Limited Announces Publication of PAT-DX1 Preclinical Data in JCI – Insight – BioSpace
Patrys Limited, a therapeutic antibody development company, has announced the publication of preclinical data for its therapeutic…
Series of preclinical studies demonstrate the therapeutic potential of PAT-DX1, a first-in-class, synthetically lethal DNA-binding antibody in primary brain cancers and brain metastases.MELBOURNE–(BUSINESS WIRE)– Patrys Limited (ASX:PAB), a therapeutic…
Continue Reading
-
Business20 hours agoThese 4 ASX mining stocks are rocketing as the rare earths boom intensifies
-
General18 hours agoBunbury man Stanley J Clemons sentenced for shooting neighbour’s dog
-
Noosa News8 hours agoWarm weather could make way for rain with ‘damaging winds, large hail’
-
Noosa News20 hours agoLung cancer researchers identify ‘breakthrough’ patterns predictive of treatment success